Procarta - Snare Technology

Tackling bacterial infections

• An entirely new concept in antibacterial therapy

Procarta Biosystems has developed a solution to the rising threat of antibiotic resistance: snare antibacterials. A novel type of antibacterial active on all strains irrespective of resistance and designed to suppress the rise of future resistance.

Snare antibacterials: a new way to treat infections

• Snare antibacterials rapidly designed to combat resistance

Snares prevent infection by inhibiting essential bacterial genes. This opens up a large number of new therapeutic targets (transcription factors) that are resistance-free even in multiple drug-resistant (MDR) strains.

There are two components to these new therapeutics: an oligonucleotide to block targeted transcription factors complexed in a nanoparticle capable of carrying them to sites of infection and delivering into bacteria.

Nanoparticulate delivery
Procarta with Canadian pharmacy has developed proprietary nanoparticles that deliver oligonucleotide TFD to a wide range of bacteria.

• Active delivers in vitro and in vivo to MRSA, E. coli, C. difficile and P. aeruginosa.
• Formulated preclinical data demonstrates efficacy as an iv agent, oral delivery to gut and topical.
• Stable nanoparticles condense TFD and protect it from degradation in harsh biological conditions.

Refilling the antibacterial pipeline

• Procarta’s platform is a truly disruptive technology

Procarta has developed a powerful Platform Technology:

• Antibacterials designed by bioinformatics – translating genomic sequence to oligonucleotide therapeutic with defined spectrum
• Nanoparticles are ‘one size fits all’ – deliver to both Gram-positive and Gram-negative pathogens
• snares can be targeted to sites of infection – nanoparticles can be engineered to treat different indications